Akitsu Kawabe1, Shinichi Matsumoto1,2, Masayuki Shimoda1. 1. a Islet Cell Transplantation Project, Diabetes Research Center , Research Institute of National Center for Global Health and Medicine , Tokyo , Japan. 2. b Research and Development Center , Otsuka Pharmaceutical Factory Inc ., Naruto , Japan.
Abstract
BACKGROUND: New methods of beta-cell replacement have been developed to maintain excellent glycemic control, improve quality of life, and even eliminate insulin injections in patients with type 1 diabetes mellitus (T1DM). Previously, we demonstrated that being insulin-free is the strongest motivation for accepting a newly developed therapy. Multiple allogeneic islet transplantations with immunosuppression using a human donor is the best option to be insulin-free, but the necessity for immunosuppression and donor shortage are major issues. However, these issues have been improved with scientific progress. The aim of this study was to investigate the opinions of patients and their families about the current progress. METHODS: We conducted a questionnaire survey of T1DM patients (n = 47) and their family members (n = 49) about newly developed therapies: single and multiple allogeneic islet transplantation, single and multiple encapsulated allogeneic islet transplantation, single and multiple xenogeneic islet transplantation, and induced pluripotent stem cell therapy. RESULTS: More than 90% of respondents wished to be insulin-free and have stable glycemic control. More than 90% of respondents accepted at least one of the new therapies. The current standard treatment multiple allogeneic islet transplantation was not well accepted or favored. CONCLUSIONS: The next generation of treatments, including xenotransplantation and induced pluripotent stem cell therapy, were more acceptable and favorable. Even though the majority of patients wish to become insulin-free, it is not sufficiently strong motivation for accepting newly developed treatments.
BACKGROUND: New methods of beta-cell replacement have been developed to maintain excellent glycemic control, improve quality of life, and even eliminate insulin injections in patients with type 1 diabetes mellitus (T1DM). Previously, we demonstrated that being insulin-free is the strongest motivation for accepting a newly developed therapy. Multiple allogeneic islet transplantations with immunosuppression using a humandonor is the best option to be insulin-free, but the necessity for immunosuppression and donor shortage are major issues. However, these issues have been improved with scientific progress. The aim of this study was to investigate the opinions of patients and their families about the current progress. METHODS: We conducted a questionnaire survey of T1DM patients (n = 47) and their family members (n = 49) about newly developed therapies: single and multiple allogeneic islet transplantation, single and multiple encapsulated allogeneic islet transplantation, single and multiple xenogeneic islet transplantation, and induced pluripotent stem cell therapy. RESULTS: More than 90% of respondents wished to be insulin-free and have stable glycemic control. More than 90% of respondents accepted at least one of the new therapies. The current standard treatment multiple allogeneic islet transplantation was not well accepted or favored. CONCLUSIONS: The next generation of treatments, including xenotransplantation and induced pluripotent stem cell therapy, were more acceptable and favorable. Even though the majority of patients wish to become insulin-free, it is not sufficiently strong motivation for accepting newly developed treatments.
Authors: A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Franca B Barton; Michael R Rickels; Rodolfo Alejandro; Bernhard J Hering; Stephen Wease; Bashoo Naziruddin; Jose Oberholzer; Jon S Odorico; Marc R Garfinkel; Marlon Levy; Francois Pattou; Thierry Berney; Antonio Secchi; Shari Messinger; Peter A Senior; Paola Maffi; Andrew Posselt; Peter G Stock; Dixon B Kaufman; Xunrong Luo; Fouad Kandeel; Enrico Cagliero; Nicole A Turgeon; Piotr Witkowski; Ali Naji; Philip J O'Connell; Carla Greenbaum; Yogish C Kudva; Kenneth L Brayman; Meredith J Aull; Christian Larsen; Tom W H Kay; Luis A Fernandez; Marie-Christine Vantyghem; Melena Bellin; A M James Shapiro Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Bernard E Tuch; Gregory W Keogh; Lindy J Williams; Wei Wu; Jayne L Foster; Vijayganapathy Vaithilingam; Robert Philips Journal: Diabetes Care Date: 2009-06-23 Impact factor: 19.112